Herantis Pharma
1.49
EUR
-1.97 %
Corporate customer
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
4,230 following
Income statement
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
growth-% | 150.0 % | |||||||||
EBITDA | -8.5 | -9.7 | -8.1 | 0.2 | -5.3 | -5.0 | -5.4 | -6.0 | ||
EBIT (adj.) | -8.1 | -12.5 | -8.0 | 0.2 | -5.3 | -5.0 | -5.4 | -6.0 | ||
EBIT | -8.1 | -12.5 | -8.0 | 0.2 | -5.3 | -5.0 | -5.4 | -6.0 | ||
Profit before taxes | -8.6 | -12.8 | -9.3 | 0.3 | -5.3 | -5.0 | -5.4 | -6.0 | ||
Net income | -8.6 | -12.8 | -9.3 | 0.3 | -5.3 | -5.0 | -5.4 | -6.0 | ||
EPS (adj.) | -0.88 | -1.15 | -0.55 | 0.01 | -0.26 | -0.21 | -0.23 | -0.25 | ||
growth-% | -1,983.9 % | |||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|---|---|
EBITDA-% | -213,375.0 % | -243,525.0 % | -201,825.0 % | 3,850.0 % | -52,560.0 % | -49,520.0 % | -54,342.5 % | -59,532.9 % | ||
EBIT-% (adj.) | -201,775.0 % | -311,525.0 % | -199,825.0 % | 3,850.0 % | -52,560.0 % | -49,520.0 % | -54,342.5 % | -59,532.9 % | ||
EBIT-% | -201,775.0 % | -311,525.0 % | -199,825.0 % | 3,850.0 % | -52,560.0 % | -49,520.0 % | -54,342.5 % | -59,532.9 % | ||
ROE | -226.6 % | -396.1 % | 1,541.2 % | 12.0 % | -213.4 % | -2,116.2 % | 221.0 % | 73.0 % | ||
ROI | -109.1 % | -119.5 % | -151.8 % | 3.3 % | -139.4 % | -180.1 % | -362.3 % | -2,381.3 % |
Valuation
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|---|---|
Share price (EUR) | 5.23 | 7.37 | 4.15 | 2.40 | 1.65 | 1.58 | 1.49 | 1.49 | 1.49 | 1.49 |
Shares | 9.8 | 11.1 | 16.9 | 20.2 | 20.2 | 23.9 | 23.9 | 23.9 | ||
Market cap | 40.5 | 26.6 | 27.9 | 31.9 | 30.0 | 35.6 | 35.6 | 35.6 | ||
Enterprise value | 34.4 | 26.4 | 26.5 | 25.4 | 30.1 | 35.5 | 41.0 | 46.9 | ||
EV/S | - | - | 8,593.4 | 6,606.4 | 6,613.7 | 6,360.3 | 3,008.0 | 3,554.5 | 4,097.9 | 4,693.2 |
EV/EBITDA | - | - | - | - | - | 165.2 | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | 165.2 | - | - | - | - |
EV/EBIT | - | - | - | - | - | 165.2 | - | - | - | - |
P/E (adj.) | - | - | - | - | - | 114.2 | - | - | - | - |
P/E | - | - | - | - | - | 114.2 | - | - | - | - |
P/B | - | - | 5.3 | - | - | 6.8 | 143.0 | 137.8 | - | - |
P/S | - | - | 10,122.9 | 6,662.4 | 6,976.2 | 7,963.6 | 3,004.0 | 3,555.3 | 3,555.3 | 3,555.3 |
Dividend yield | ||||||||||
Equity ratio | 46.2 % | -14.7 % | -1.1 % | 69.9 % | 7.6 % | 9.4 % | -2,070.5 % | -4,451.8 % | ||
Gearing ratio | -80.6 % | 19.6 % | 2,071.4 % | -136.0 % | 19.0 % | -3.1 % | -104.8 % | -102.2 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | ||||||
EBITDA | -2.4 | 2.6 | 0.2 | -2.8 | -2.5 | ||||
EBIT | -2.4 | 2.6 | 0.2 | -2.8 | -2.5 | ||||
Profit before taxes | -1.8 | 2.1 | 0.3 | -2.8 | -2.5 | ||||
Net income | -1.8 | 2.1 | 0.3 | -2.8 | -2.5 |